Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Suman P, Mishra S, Chander H. High expression of FBP17 in invasive breast cancer cells promotes invadopodia formation. Med Oncol 2018;35:71. [PMID: 29651632 DOI: 10.1007/s12032-018-1132-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Accepted: 04/08/2018] [Indexed: 01/23/2023]

For:	Suman P, Mishra S, Chander H. High expression of FBP17 in invasive breast cancer cells promotes invadopodia formation. Med Oncol 2018;35:71. [PMID: 29651632 DOI: 10.1007/s12032-018-1132-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Accepted: 04/08/2018] [Indexed: 01/23/2023]

Number

Cited by Other Article(s)

Wang CJ, Cui L, Li SS, Ma HH, Wang D, Lian HY, Zhao YZ, Zhang LP, Li WJ, Zhang Q, Zhao XX, Yang Y, Huang XT, Liu W, Wang YZ, Wu WS, Wang TY, Zhang R, Li ZG. Genetic Landscape and Its Prognostic Impact in Children With Langerhans Cell Histiocytosis. Arch Pathol Lab Med 2025;149:175-190. [PMID: 38749502 DOI: 10.5858/arpa.2023-0236-oa] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/18/2024] [Indexed: 01/29/2025]

Abstract

CONTEXT.—

Langerhans cell histiocytosis (LCH) is a rare myeloid neoplasm that predominantly affects young children.

OBJECTIVE.—

To investigate genetic alterations and their correlation with clinical characteristics and prognosis in pediatric LCH.

DESIGN.—

We performed targeted sequencing to detect mutations in LCH lesions from pediatric patients.

RESULTS.—

A total of 30 genomic alterations in 5 genes of the MAPK pathway were identified in 187 of 223 patients (83.9%). BRAF V600E (B-Raf proto-oncogene, serine/threonine kinase) was the most common mutation (51.6%), followed by MAP2K1 (mitogen-activated protein kinase kinase 1) alterations (17.0%) and other BRAF mutations (13.0%). ARAF (A-Raf proto-oncogene, serine/threonine kinase) and KRAS (KRAS proto-oncogene, GTPase) mutations were relatively rare (2.2% and 0.9%, respectively). Additionally, FNBP1 (formin-binding protein 1)::BRAF fusion and MAP3K10 (mitogen-activated protein kinase kinase 10) mutations A17T and R823C were identified in 1 case each, with possible constitutive activation of ERK1/2 phosphorylation. BRAF V600E was more frequent in patients with risk organ involvement, while MAP2K1 mutation was more prevalent in patients with single-system LCH (P = .001). BRAF V600E was associated with craniofacial bone, skin, liver, spleen, and ear involvement (all P < .05). Patients with other BRAF mutations had a higher proportion of spinal column involvement (P = .006). Univariate analysis showed a significant difference in progression-free survival among the 4 molecular subgroups for patients treated with first-line therapy (P = .02). According to multivariate analysis, risk organ involvement was the strongest independent adverse prognostic factor (hazard ratio, 8.854; P < .001); BRAF or MAP2K1 mutation was not an independent prognostic factor.

CONCLUSIONS.—

Most pediatric patients with LCH carry somatic mutations involving the MAPK pathway, correlating with clinical characteristics and outcomes for first-line chemotherapy.

Collapse

Affiliation(s)

Chan-Juan Wang From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Lei Cui From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Shuang-Shuang Li MyGenostics Inc, Beijing, China (S-S Li)
Hong-Hao Ma From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Dong Wang From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Hong-Yun Lian From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Yun-Ze Zhao From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Li-Ping Zhang From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Wei-Jing Li From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Qing Zhang From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Xiao-Xi Zhao From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Ying Yang From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Xiao-Tong Huang From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Wei Liu the Department of Hematology Oncology, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, China (Liu)
Yi-Zhuo Wang the Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China (Y-Z Wang)
Wan-Shui Wu and the Department of Pediatrics, Beijing Shijitan Hospital, Capital Medical University, Beijing, China (Wu)
Tian-You Wang From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Rui Zhang From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)
Zhi-Gang Li From the Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute (C-J Wang, Cui, W-J Li, Q Zhang, X-X Zhao, Huang, Z-G Li) and Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China National Key Discipline of Pediatrics, Capital Medical University, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li) Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China (C-J Wang, Cui, Ma, D Wang, Lian, Y-Z Zhao, L-P Zhang, W-J Li, Q Zhang, X-X Zhao, Yang, Huang, T-Y Wang, R Zhang, Z-G Li)

Collapse

Saha S, Mandal A, Ranjan A, Ghosh DK. Membrane tension sensing formin-binding protein 1 is a neuronal nutrient stress-responsive Golgiphagy receptor. Metabolism 2025;162:156040. [PMID: 39341273 DOI: 10.1016/j.metabol.2024.156040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2024] [Revised: 09/23/2024] [Accepted: 09/23/2024] [Indexed: 09/30/2024]

Das S, Maiti S. Probing the ligand binding specificity of FNBP4 WW domains and interaction with FH1 domain of FMN1. Curr Res Struct Biol 2023;7:100119. [PMID: 38188541 PMCID: PMC10770428 DOI: 10.1016/j.crstbi.2023.100119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 12/05/2023] [Accepted: 12/06/2023] [Indexed: 01/09/2024] Open

Zhang J, Li X, Zhou Y, Lin M, Zhang Q, Wang Y. FNBP1 Facilitates Cervical Cancer Cell Survival by the Constitutive Activation of FAK/PI3K/AKT/mTOR Signaling. Cells 2023;12:1964. [PMID: 37566043 PMCID: PMC10417648 DOI: 10.3390/cells12151964] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 07/25/2023] [Accepted: 07/27/2023] [Indexed: 08/12/2023] Open

Feng D, Wang J, Shi X, Li D, Wei W, Han P. Membrane tension-mediated stiff and soft tumor subtypes closely associated with prognosis for prostate cancer patients. Eur J Med Res 2023;28:172. [PMID: 37179366 PMCID: PMC10182623 DOI: 10.1186/s40001-023-01132-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Accepted: 05/02/2023] [Indexed: 05/15/2023] Open

Zheng KW, Zhang CH, Wu W, Zhu Z, Gong JP, Li CM. FNBP4 is a Potential Biomarker Associated with Cuproptosis and Promotes Tumor Progression in Hepatocellular Carcinoma. Int J Gen Med 2023;16:467-480. [PMID: 36760683 PMCID: PMC9907010 DOI: 10.2147/ijgm.s395881] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Accepted: 01/26/2023] [Indexed: 02/05/2023] Open

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors that lacks an efficient therapeutic approach because of its elusive molecular mechanisms. This study aimed to investigate the biological function and potential mechanism of formin-binding protein 4 (FNBP4) in HCC.

Methods

FNBP4 expression in tissues and cells were detected by quantitative real-time PCR (qRT‒PCR), Western blot, and immunohistochemistry (IHC). The Kaplan-Meier method was used to explore the correlation between the FNBP4 expression and clinical survival. MTT, EdU incorporation, colony formation, and Transwell assays were performed to evaluate the function of FNBP4 in cell proliferation and migration in vitro. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was used to explore the potential mechanism of FNBP4. The prognostic risk signature and nomogram were constructed to demonstrate the prognostic value of FNBP4.

Results

We found that FNBP4 was upregulated in patients with HCC and associated with poor overall survival (OS). Furthermore, knockdown of FNBP4 inhibited the proliferation and migration in HCC cells. Then, we performed a KEGG pathway analysis of the coexpressed genes associated with FNBP4 and found that FNBP4 may be associated with tumor-related signaling pathways and cuproptosis. We verified that FNBP4 could cause cell cycle progression and inactivation of the hippo signaling pathway. A prognostic risk signature containing three FNBP4-related differentially expressed cuproptosis regulators (DECRs) was established and can be used as an independent risk factor to evaluate the prognosis of patients with HCC. In addition, a nomogram including a risk score and clinicopathological factors was used to predict patient survival probabilities.

Conclusion

FNBP4, as a potential biomarker associated with cuproptosis, promotes HCC cell proliferation and metastasis. We provide a new potential strategy for HCC treatment by targeting FNBP4.

Collapse

Kreider-Letterman G, Castillo A, Mahlandt EK, Goedhart J, Rabino A, Goicoechea S, Garcia-Mata R. ARHGAP17 regulates the spatiotemporal activity of Cdc42 at invadopodia. J Cell Biol 2022;222:213782. [PMID: 36571786 PMCID: PMC9794838 DOI: 10.1083/jcb.202207020] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 10/18/2022] [Accepted: 11/28/2022] [Indexed: 12/27/2022] Open

Prognostic significance of CHAC1 expression in breast cancer. Mol Biol Rep 2022;49:8517-8526. [PMID: 35729480 DOI: 10.1007/s11033-022-07673-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Accepted: 05/31/2022] [Indexed: 10/18/2022]

Wang Z, Tian Z, Song X, Zhang J. Membrane tension sensing molecule-FNBP1 is a prognostic biomarker related to immune infiltration in BRCA, LUAD and STAD. BMC Immunol 2022;23:1. [PMID: 34998385 PMCID: PMC8742955 DOI: 10.1186/s12865-021-00475-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 12/28/2021] [Indexed: 12/15/2022] Open

Abstract

Background

Formin-binding protein 1/17 (FNBP1/FBP17), as a membrane-bound protein, is wildly expressed in eukaryotic cells and performs a critical role in tumor tumorigenesis and progression. However, the relationship between FNBP1 and immune infiltrating cells, prognostic value in patients still require comprehensive understanding. We purposed to explore the correlations of FNBP1 expression, prognosis and immune infiltration levels in various cancers.

Method

The expression and survival data of FNBP1 were collected from Oncomine, TIMER, GEPIA, Kaplan–Meier Plotter and PrognoScan databases. Correlations between FNBP1 and immune infiltrates were analyzed in TIMER and GEPIA databases.

Results

Compared with normal tissues, FNBP1 is significantly differentially expressed in a variety of tumor tissues. FNBP1 has significant and complex effects on the prognosis of kinds of cancers. High-expression was obviously correlated with better prognosis in breast carcinoma and lung adenocarcinoma, while worse prognosis in stomach adenocarcinoma. Besides, FNBP1 had a correlation with various immune infiltrating cells and diverse immune gene markers in breast invasive carcinoma (BRCA), lung adenocarcinoma (LUAD), and stomach adenocarcinoma (STAD). FNBP1 was also positively correlated with the adjustment of CD8+ cells, T cells, M2 macrophage, neutrophils, monocyte, Th1 cells, T regulatory cells (Treg) and Tumor-associated macrophages (TAMs). The expression level of FNBP1 is closely positively correlated with the expression level of multiple immune checkpoints in the three cancers. In addition, FNBP1 is significantly positively correlated with the expression levels of a variety of immunosuppressive molecules.

Conclusion

Our findings reveal FNBP1 can serve as a significant biomarker to influence the prognosis and the immune infiltrating levels in different cancers. The differential expression of FNBP1 might not only contribute to the judgment of metastatic and non-metastatic tumors but also in the immune escape by upregulating the expression of immune checkpoints.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12865-021-00475-z.

Collapse

OUP accepted manuscript. Carcinogenesis 2022;43:494-503. [DOI: 10.1093/carcin/bgac015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 01/08/2022] [Accepted: 01/28/2022] [Indexed: 11/12/2022] Open

Sp1-Induced FNBP1 Drives Rigorous 3D Cell Motility in EMT-Type Gastric Cancer Cells. Int J Mol Sci 2021;22:ijms22136784. [PMID: 34202606 PMCID: PMC8267707 DOI: 10.3390/ijms22136784] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Revised: 06/21/2021] [Accepted: 06/21/2021] [Indexed: 12/11/2022] Open

Cao R, Shao J, Zhang W, Lin Y, Huang Z, Li Z. Silencing long intergenic non-protein coding RNA 00987 inhibits proliferation, migration, and invasion of osteosarcoma cells by sponging miR-376a-5p to regulate FNBP1 expression. Discov Oncol 2021;12:18. [PMID: 35201476 PMCID: PMC8777572 DOI: 10.1007/s12672-021-00412-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2021] [Accepted: 05/24/2021] [Indexed: 01/19/2023] Open

Tertrais M, Bigot C, Martin E, Poincloux R, Labrousse A, Maridonneau-Parini I. Phagocytosis is coupled to the formation of phagosome-associated podosomes and a transient disruption of podosomes in human macrophages. Eur J Cell Biol 2021;100:151161. [PMID: 33836409 DOI: 10.1016/j.ejcb.2021.151161] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Revised: 03/08/2021] [Accepted: 03/29/2021] [Indexed: 01/10/2023] Open

Niland S, Eble JA. Hold on or Cut? Integrin- and MMP-Mediated Cell-Matrix Interactions in the Tumor Microenvironment. Int J Mol Sci 2020;22:ijms22010238. [PMID: 33379400 PMCID: PMC7794804 DOI: 10.3390/ijms22010238] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 12/21/2020] [Accepted: 12/23/2020] [Indexed: 02/07/2023] Open

Suman P, Mishra S, Chander H. High formin binding protein 17 (FBP17) expression indicates poor differentiation and invasiveness of ductal carcinomas. Sci Rep 2020;10:11543. [PMID: 32665637 PMCID: PMC7360568 DOI: 10.1038/s41598-020-68454-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Accepted: 05/29/2020] [Indexed: 12/20/2022] Open

Casamento A, Boucrot E. Molecular mechanism of Fast Endophilin-Mediated Endocytosis. Biochem J 2020;477:2327-2345. [PMID: 32589750 PMCID: PMC7319585 DOI: 10.1042/bcj20190342] [Citation(s) in RCA: 68] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Revised: 05/11/2020] [Accepted: 05/18/2020] [Indexed: 12/13/2022]

Thuault S, Mamelonet C, Salameh J, Ostacolo K, Chanez B, Salaün D, Baudelet E, Audebert S, Camoin L, Badache A. A proximity-labeling proteomic approach to investigate invadopodia molecular landscape in breast cancer cells. Sci Rep 2020;10:6787. [PMID: 32321993 PMCID: PMC7176661 DOI: 10.1038/s41598-020-63926-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Accepted: 04/06/2020] [Indexed: 12/27/2022] Open

KIBRA Team Up with Partners to Promote Breast Cancer Metastasis. Pathol Oncol Res 2019;26:627-634. [DOI: 10.1007/s12253-019-00660-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Accepted: 04/01/2019] [Indexed: 02/06/2023]